Asuragen to Present at 29th Annual Piper Jaffray Healthcare Conference
Austin, Texas — 11/21/2017 — Asuragen, Inc., a global molecular diagnostics product company changing the way patients are treated in genetics and oncology by bringing complex molecular tests to hospital and reference labs, announced that Matthew McManus, M.D., Ph.D., president and chief executive officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017 at 10:50 a.m. Eastern Time in New York.
Asuragen is a molecular diagnostic company changing the way patients are treated in genetics and oncology. The quality, simplicity and sensitivity of its products brings precision medicine within reach. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit www.asuragen.com.
SVP, Corporate Development & CFO
2150 Woodward St., Suite 100
Austin, TX 78744
Pure Communications, Inc.